Results of all pathologist for phase II (n=39)
| Pathologist | Percentage of cases ‘indefinite for dysplasia’ | Percentage agreement (three categories)* | Consensus LGD and HGD cases underdiagnosed as NDBO (n (%)) n=23 |
| Core pathologists | |||
| 1 | 17.9 | 89.7 | 0 |
| 2 | 10.3 | 87.2 | 2 (8.7) |
| 3 | 28.2 | 71.8 | 2 (8.7) |
| 4 | 20.5 | 87.2 | 2 (8.7) |
| 5 | 17.9 | 82.1 | 0 |
| New core pathologists | |||
| B | 7.7 | 74.4 | 2 (8.7) |
| E | 25.6 | 69.2 | 1 (4.3) |
| J | 12.8 | 71.8 | 1 (4.3) |
| New core pathologist after phase 1 | |||
| F | 33.3 | 61.5 | 1 (4.3) |
| Aspirant panel members | |||
| A | 2.6 | 56.4 | 7 (30.4) |
| C | 7.7 | 66.7 | 0 |
| D | 12.8 | 64.1 | 0 |
| G | 12.8 | 66.7 | 2 (8.7) |
| H | 12.8 | 69.2 | 1 (4.3) |
| I | 15.4 | 76.9 | 1 (4.3) |
| Benchmarkvalue† | ≤38 | ≥56 | ≤3 (13) |
dark grey, score does not fall within benchmark values
light grey, score falls within benchmark values
*NDBO/IND/LGD+HGD.
†Based on nine core pathologists.
HGD, high-grade dysplasia; IND, indefinite for dysplasia; LGD, low-grade dysplasia; NDBO, non-dysplastic Barrett’s oesophagus.